Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A study for people who have had a kidney transplant to see the benefits and risks of taking belatacept instead of their current anti-rejection medicine. Etude pour les personnes ayant eu une transplantation rénale afin de voir les bénéfices et les risques de la prise de bélatacept au lieu de leur traitement anti-rejet actuel
To evaluate patient and functional graft survival in maintenance renal transplant recipients (6-60 Months post transplantation) converted from CNI to belatacept-based immunosupression as compared to t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Phase 4: Investigational study to evaluate metformin XR monotherapy versus metformin IR monotherapy in subjects with type 2 diabetes
To determine if monotherapy with 2000 mg metformin extended release is non-inferior to monotherapy with 2000 mg immediate release in adult patients with type 2 diabetes who have inadequate glycemic ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). Revised Protocol 05 incorporating Protocol Amendments 13 (dated 10-Feb-2011) + Pharmacogenetics Blood Sample Amendment 01 Site Specific - 04-Aug-05 + Exploratory Research Substudy Amendment Number 2 - Site Specific - Selected Sites, version 1.0 dated 29-Jun-06
• Evaluate the effects of belatacept, relative to CsA, on the composite of subject and graft survival by 12 months. • Evaluate the effects of belatacept, relative to CsA, on the composite of measured ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
This study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy. Revised Protocol 03 incorporating Amendments 02 (v1.0, Date 06-Dec-2006), 03 (v1.0, Date 05-Mar-2007), 08 (v1.0, Date 22-Dec-2008) and Administrative Letters 01, 02 & 03. And Pharmacogenetics Blood Sample Amendment 01 - Site Specific (v2.0, Date: 02-Nov-06). + Protocol amendment 04 (Biopsy substudy) - Site specific
*Induction Period (IP): Compare the proportion of subjects in clinical response (defined as a reduction from baseline in Mayo score of >= 3 points and >= 30%, with an accompanying decrease from baseli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase II study to investigate the effect of discontinuation of Dasatinib treatment in CP-CML patients with stable CMR
The primary objective of this study is to assess the rate of major molecular response (MMR), defined as BCR-ABL transcripts <0.1% on International Scale (IS) at 12 months after dasatinib discontinuati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Revised Protocol #05, incorporating Protocol Amendments 04, 07, 08 and 10; + Pharmacokinetics Blood Sample Amendment #03 dated 18-Oct-05 + Amendment #06, dated 24-Feb-06
To estimate the objective response rate (as defined by the WHO criteria modified by the SWOG) in patients with TCC receiving vinflunine, who have had documented progression within 12 months after the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Protocol CA165020: A Randomized, Two -Cohort Phase II Study of Two Doses of BMS-275183 Given On a Weekly Schedule in Patients with Pre-Treated Non- Small Cell Lung Cancer
To assess the clinical activity of each of two doses of BMS-275183 given PO as a single dose once a week on a continuous weekly schedule, as measured by the tumor response rate in two seperate cohorts...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy Revised Protocol 02, incorporating Protocol Amendments 02 and 04 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 20-Nov-09)
To compare the clinical benefit rate (CBR) in patients receiving the BMS-690514/letrozole combination relative to the lapatinib/letrozole combination.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
To estimate abatacept steady-state trough concentration (Cmin) at Day 113 in children and adolescents with pJIA aged 6 to 17.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant